ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$2.07
-0.15 (-6.76%)
Financial Highlights (FY 2025)
Revenue
52.71M
Net Income
7.77M
Gross Margin
47.9%
Profit Margin
14.7%
Rev Growth
+19.4%
D/E Ratio
1.42
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 47.9% | 47.9% | 47.9% |
| Operating Margin | 17.5% | 17.4% | 17.9% |
| Profit Margin | 14.7% | 15.4% | 12.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Gross Profit | 25.24M | 25.34M | 19.99M |
| Operating Income | 9.21M | 9.22M | 7.47M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Gross Margin | 47.9% | 47.9% | 47.9% |
| Operating Margin | 17.5% | 17.4% | 17.9% |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| Rev Growth | +19.4% | -7.3% | -1.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 170.60M | 170.56M | 157.74M |
| Total Equity | 120.38M | 116.15M | 124.94M |
| D/E Ratio | 1.42 | 1.47 | 1.26 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |